This large real world study compares the effectiveness of antipsychotic treatments on mortality, psychiatric re-hospitalisation and treatment failure outcomes in patients with schizophrenia ...

Net sales of Cobenfy, whose success is imperative for Bristol Myers, totaled $27 million in the first quarter, handily ...

Schizophrenia is a complex mental disorder affecting over 20 million people worldwide. Current research suggests accelerated brain ageing, indicated by rising neurofilament light protein levels, as a ...

In the months after 24-year-old D.J. was diagnosed with schizophrenia, he searched online for answers to questions that felt urgent and existential.

Cobenfy, Bristol Myers Squibb’s once-promising schizophrenia drug, just failed its Phase III ARISE trial as an add-on therapy ...

This groundbreaking work not only provides a potential marker for examining cognitive rigidity among schizophrenia patients ... making it harder to see real-time brain-behavior connections.

At least some of schizophrenia's symptoms are ... "There's a lot that's going to be learned in the real world." Researchers, physicians and patients are facing a mountain of unanswered questions.

Advertising Some patients who tried the compound had symptoms related to schizophrenia — suspiciousness ... lot that’s going to be learned in the real world.” In Spokane, group home staff ...

For some patients, simulated situations controlled by therapists may be less overwhelming than real-life exposure therapy.

1 Department of Radiology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China 2 Chongqing General Hospital, Chongqing University, Chongqing, China Background: The characteristics of ...